COMPANY PROFILE

RenBio

A privately-held, preclinical biotechnology company developing best-in-class antibody therapeutics and a next-generation antibody delivery platform

New York City, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About RenBio

RenBio is a preclinical biotechnology company founded in 2016 and based in New York. The company is focused on developing novel antiviral antibody therapeutics and a next-generation antibody delivery platform. Its proprietary MYO Technology platform is a muscle-based, non-viral gene delivery system that allows for the production of therapeutic antibodies in the body.

RenBio's business model revolves around the development and commercialization of its antibody-based therapies. The company's primary clients are likely to be larger pharmaceutical and biotechnology companies that may license or acquire its technologies. The company operates in the highly competitive biotechnology market, with a focus on infectious diseases and other indications that can be addressed with antibody therapeutics.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: New York City, United States
Employees: 7
Open positions: None listed
Dealroom signal: 58.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jul 2024	$2.9M	—	Undisclosed	↗
GRANTOther financing	Oct 2022	$2M	—	DARPA	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

RenBio website traffic

Latest recorded traffic for RenBio is 2.4K monthly website visits, up 33.3% over the last three months. RenBio's team declined 46.2% over the past year.

Latest monthly visits2.4K 3-month web change+33.3% 1-year team growth-46.2%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational	12	$3.9M	$15M
SISolid IOMaking immunotherapies accessible at scale.	Helsinki, Finland	Operational
PBPattern BiosciencesBuilds biomolecular computers that run molecular programs in cells to treat cancer and other diseases	South San Francisco, United States	Operational
GBGenerare BioscienceBioactive molecule discovery platform from microbial DNA	Paris, France	Operational
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
SYSymbiomicsHigh-performance agricultural biologicals using microbiome and genomic technologies	Florianópolis, Brazil	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational